Compare · NAUT vs WAT
NAUT vs WAT
Side-by-side comparison of Nautilus Biotechnology Inc. (NAUT) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NAUT and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $43.64B, about 158.8x NAUT ($274.9M).
- Over the past year, NAUT is up 110.9% and WAT is up 30.6% - NAUT leads by 80.3 points.
- WAT has been more active in the news (4 items in the past 4 weeks vs 3 for NAUT).
- WAT has more recent analyst coverage (25 ratings vs 9 for NAUT).
- Company
- Nautilus Biotechnology Inc.
- Waters Corporation
- Price
- $2.06-4.19%
- $436.95-1.63%
- Market cap
- $274.9M
- $43.64B
- 1M return
- +112.15%
- +1.57%
- 1Y return
- +110.89%
- +30.56%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- 1995
- News (4w)
- 3
- 4
- Recent ratings
- 9
- 25
Nautilus Biotechnology Inc.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the human proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company is headquartered in Seattle, Washington.
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest NAUT
- Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
- Roth Capital initiated coverage on Nautilus Biotechnology with a new price target
- SEC Form EFFECT filed by Nautilus Biotechnology Inc.
- SEC Form 424B5 filed by Nautilus Biotechnology Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.
- Nautilus Biotechnology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form S-3 filed by Nautilus Biotechnology Inc.
- Leerink Partners initiated coverage on Nautilus Biotechnology with a new price target
- Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms
- Amendment: SEC Form SCHEDULE 13D/A filed by Nautilus Biotechnology Inc.
Latest WAT
- Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
- Director Knight Heather was granted 57 shares, increasing direct ownership by 4% to 1,338 units (SEC Form 4)
- Director Jiang Wei was granted 57 shares, increasing direct ownership by 2% to 3,630 units (SEC Form 4)
- Waters Corporation Schedules Third Quarter 2026 Earnings Conference Call
- Waters Sets Benchmark for Standardized Spectral Flow Cytometry with Commercial Launch of BD FACSDiscover A7 Cell Analyzer
- Waters Corporation to Present at the J.P. Morgan U.S. All Stars Conference
- UBS resumed coverage on Waters with a new price target
- SEC Form 3 filed by new insider Wu Tong (Nmn)
- Waters upgraded by Piper Sandler with a new price target
- Waters Corporation to Present at the Wells Fargo Healthcare Conference